|Bid||56.26 x 1100|
|Ask||57.88 x 1300|
|Day's range||57.04 - 57.64|
|52-week range||52.65 - 79.67|
|Beta (5Y monthly)||1.36|
|PE ratio (TTM)||25.28|
|Forward dividend & yield||0.54 (0.96%)|
|Ex-dividend date||03 May 2022|
|1y target est||N/A|
Cross Country Healthcare and AnheuserBusch InBev are part of Zacks Bull and Bear of the Day article.
BUD may have beaten the number, but the EPS estimates for this stock keep dipping lower.
Owners of Anheuser-Busch InBev (NYSE: BUD) stock beat the market in April as shares rose 2% compared to a 9% dive in the S&P 500, according to data provided by S&P Global Market Intelligence. The boost was powered by rising optimism about InBev's sales outlook, which the company confirmed in a recent earnings report. Investors heard from several of InBev's peers last month, including beverage giant Coca-Cola and alcoholic drink specialist Constellation Brands, which indicated solid demand in the industry.